Kornimate/medical-research-clean huggingface dataset:
safety and efficacy of the elastimed's sacs 2.0 - smart active compression stocking for the treatment of venous edema

Conditions: Edema Leg; Compression; Vein

Summary: device efficacy: the primary efficacy assessment will be defined as successful if the edema volume will be reduced over time after using the sacs 2.0 device. treatment and edema evaluation will be performed in comparison to a standard compression bandage. the treatment will be performed for several hours during the subject's daily rest time. the measurements will be performed daily before treatment initiation and without the device on the leg (baseline) (t0); and after four hours of device operation. the edema volume will be measured by a calf circumference measurement.


Eligibility criteria:
inclusion criteria: 1. subjects must be between 18 to 80 years old 2. venous edema patients diagnosed by an indent in the skin following finger pressure. 3. venous edema in both calves 4. temporarily or permanently wheelchair users which are expected to remain so according to the investigator's discretion 5. subjects able to provide a written informed consent 6. no existence of dvt according to leg deep vein duplex test exclusion criteria as reported by patients: : 1. positive pregnancy test 2. breastfeeding woman 3. moderate or severe congestive heart failure 4. cellulitis of tissues of the lower limb. 5. infectious dermatitis of the lower limb 6. acute or within 6 weeks of a deep vein thrombosis (dvt). 7. postphlebetic patients 8. known hypersensitivity to any component of the device 9. subjects unable to provide informed consent 10. active cancer at the root of the limb or in the adjacent quadrant 11. any limitation of renal function- according to the investigator's discretion 12. any limitation of liver function - according to the investigator's discretion 13. subject who cannot commit to a month of intensive standard therapy 14. wound or other skin condition that, according to the investigator's discretion, might be aggravated by the garment 15. currently participating in another clinical trial or have completed their participation in a clinical trial within 30 days of screening 16. other physical and/or mental conditions that, according to the investigator's discretion, prevent the subject from participating in the trial and completing its assessments 17. cardiac or cerebral pacemaker or stimulator 18. patients after orthopedic / vascular injury in the lower extremities
risk assessment strategies in pulmonary embolism

Conditions: Pulmonary Embolism

Summary: the aim of this study is to evaluate different scores of risk assessment in patients with pulmonary embolism. this study aim to compare the accuracy of these scores in predicting mortality during hospital admission.

pulmonary embolism (pe) is a potentially life-threatening cardiovascular emergency with a high mortality rate.approximately 1% of all hospitalized patients and 10% of all in-hospital mortalities are pe related. adding to this, acute pe is linked to comparatively high (≥13%) short-term mortalities that occur either in hospital or within 30 days. some studies have demonstrated that pe may indicate increased 1-year mortality rates up to 25%,,. therefore, pe is considered a potentially fatal disease, although patients who escape a pe-related death are still endangered by hematologic mishaps, especially recurrence of vte and/or pe, or on the contrary, serious hemorrhage5. risk stratification of patients with acute pe is mandatory for determining the appropriate therapeutic management approach. risk classification of pe can discriminate low-risk patients, who can be medicated as outpatients, from others at high risk, in whom a profit from intensive care unit admission or even in-hospital thrombolytic therapy is expected.

Eligibility criteria:
inclusion criteria: - all patients will be subjected to the following: 1. complete history taking and clinical examination. 2. chest x-ray 3. ecg and echocardiography. 4. arterial blood gases. 5. multislice ct angiography of the chest. 6. laboratory tests and biomarkers. exclusion criteria: * 1- patients with unexpected or accidental diagnosis of pe (patients undergoing diagnostic tests for another suspected disease. 2- patients with acute left heart failure or acute respiratory failure responsible for symptoms. 3- patient with recurrent pe (only the first event was included in the analysis).
awareness in old aged patients during laryngoscopy and intubation using isolated forearm technique

Conditions: Awareness, Anesthesia; Recall Phenomenon; Inhalation; Gas

Summary: awareness during general anesthesia - that has an incidence between 0.1% and 0.9% of cases and may be more in elderly - remains a concern for anesthesiologists. awareness experiences range from isolated auditory perceptions to reports of a patient being fully awake, immobilized, and in pain. the isolated forearm technique allows assessment of consciousness of the external world (connected consciousness) through a verbal command to move the hand (of a tourniquet-isolated arm) during intended general anesthesia.

objective: to compare inhalational induction versus intravenous induction regarding awareness during laryngoscopy and intubation in elderly patients undergoing day case elective surgery.

Eligibility criteria:
inclusion criteria: * 50 american society of anesthesiologists- physical status (asa-ps) i and ii patients, * aged 60 to 80 years, * 70-80 kg, * both sexes, * with intact hearing, * undergoing elective day case surgery were included in the study. exclusion criteria: 1. uncooperative patients, 2. language barrier problems, 3. psychological disorders, 4. suspected difficult intubation, 5. history of awareness under anesthesia, 6. history of substance abuse, 7. the inability to have tourniquet on arm for the ift (e.g., lymphedema or operative site) 8. neuromuscular disorders. 9. advanced renal, hepatic, cardiac, respiratory or neurological dysfunction 10. if rapid sequence induction was indicated (not suitable for inhalation induction).

Keywords: tiva isoflurane old age
relationship between mafld and liver fibrosis progression in patients with chronic hepatitis b: a multicenter retrospective cohort study

Conditions: Hepatitis B, Chronic

Summary: this multicenter retrospective study aims to study the association between the presence of mafld and change in liver stiffness over time in untreated and treated patients with chronic hepatitis b

this project is a multicenter retrospective cohort study. all chb patients who underwent at least 2 liver stiffness assessments with a fibroscan device at least 6 months apart are eligible for enrolment. at baseline (defined as the first liver stiffness assessment) patients will be allocated to one of 4 groups (figure) based on use of antiviral therapy and presence of mafld. mafld is defined as presence of steatosis (based on ultrasound, histology or controlled attenuation parameter) in the presence of overweight (bmi \>23 for asians or \>25 for caucasians), diabetes mellitus, or at least 2 minor metabolic dysfunction criteria.(9) baseline and follow-up data on biochemistry, virology, liver stiffness and clinical outcomes will be collected for all eligible patients. in case of initiation of antiviral therapy or development of mafld during follow-up, patients will transition to the appropriate cohort from that time-point onwards. to ascertain the influence of the presence of mafld on liver stiffness progression, changes in liver stiffness will be compared within study groups (ie. cohort a vs b and cohort c vs d). to study the influence of antiviral therapy on liver stiffness progression in relation to presence of mafld, liver stiffness dynamics will be compared in cohort b vs cohort d (figure). the latter analysis will also be performed in the subgroup of patients with low levels of viremia (hbv dna \<2,000 iu/ml) and/or low levels of alt (\< 2 times the upper limit of normal).

Eligibility criteria:
inclusion criteria: * chronic hepatitis b monoinfection * at least two liver stiffness measurements more than 6 months apart * availability of data on hepatic steatosis (ultrasound, controlled attenuation parameter or histology) within 1 year of baseline exclusion criteria: * antiviral therapy with drugs other than entecavir, tenofovir disoproxil fumarate or tenofovir alafenamide (for group 2 only) * presence of concomitant liver disease such as wilson's disease, autoimmune hepatitis, hemochromatosis or alcohol abuse (\>21 alcoholic drinks/week, female's \>14/week) * presence of secondary causes of hepatic steatosis (medication, alcohol abuse) * coinfection with hcv, hiv, hev
flow mri in normal pressure hydrocephalus

Conditions: Normal Pressure Hydrocephalus

Summary: normal pressure hydrocephalus diagnosis based on quantitative study of cerebro-spinal fluid and blood flow by phase contrast magnetic resonance imaging.


Eligibility criteria:
inclusion criteria: * ventricular dilation seen on morphological magnetic resonance imaging (mri) * walking disorder * cognitive disorder * participants gave their written informed consent exclusion criteria: * contra-indication to mri * obstructive tumoral hydrocephalus * curatorship or tutorship * pregnancy or lactation * no social assurance

Keywords: normal pressure hydrocephalus flow mri dementia cerebrospinal fluid shunt
invasive diagnostic and therapeutic management of cerebral vasospasm after aneurysmatic subarachnoid hemorrhage

Conditions: Cerebral Vasospasm After Subarachnoid Hemorrhage

Summary: cerebral vasospasm(cvs) after subarachnoid hemorrhage (sah) results in a considerable amount of transient or even permanent neurological deficits and poor outcome of the patients. transluminal balloon angioplasty (tba) or intraarterial application of vasodilators represents a rescue therapy for severe cvs. indication, duration and efficacy of this treatment, however, is still under debate. aim of the study is to investigate if such a rescue treatment can significantly reduce new delayed ischemic cerebral deficits after sah. hypothesis is that the occurance of delayed infarcts can be reduced by repetetive intraarterial therapy to more than 50 %.


Eligibility criteria:
inclusion criteria: * sah (wfns 1-4) * perfusion relevant cvs * ability for mri, dsa and intraarterial treatment exclusion criteria: * extended cerebral infarcts * sah or ich from avm or flow associated aneurysm * non aneurismal sah * relevant non spastic stenosis of brain supplying arteries

Keywords: cerebral vasospasm subarachnoid hemorrhage transluminal balloon angioplasty intraarterial treatment
dexmedetomidine and neuroprotection in children undergoing general anesthesia

Conditions: Dexmedetomidine

Summary: neuroapoptosis is induced by the administration of anesthetic agents to the young brain. recent studies showed that the a2-adrenoceptor agonist, dexmedetomidine plays a trophic role during development and is neuroprotective in several settings of neuronal injury in animals. we hypothesized that neuroprotective effect of dexmedetomidine would be associated with evidence of brain injury detected by elevation of plasma concentration of glial fibrillary acid protein in children undergoing general anesthesia.

gfap measure

Eligibility criteria:
inclusion criteria: * children undergoing general anesthesia longer than 3 hours exclusion criteria: * past history of anesthesia * cardiopulmonary bypass * preexisting neurocognitive dysfunction * abnormalities of liver profile (aspartate transaminase \> 40 unit/l, alanine aminotransferase \> 40 unit/l)
effects of a mindfulness app for outpatients waitlisted for psychological interventions

Conditions: Mental Disorder

Summary: the purpose of this study is to evaluate a mindfulness-based meditation app provided to outpatients (or community participants) who are waitlisted for standard psychological care for mental health or substance use concerns.

this project aims to provide a previously validated mindfulness meditation app to up to 200 adults waitlisted for psychological services in a psychiatric hospital setting or in the broader community. outpatients (or community participants) who have been referred to and waitlisted for treatment for their mood, anxiety, alcohol, and/or substance use concerns, will be offered access to the digital intervention for 1 year. we will follow participants for 3 months to evaluate usability and psychological symptoms.

Eligibility criteria:
inclusion criteria: 1. 18-65 years of age 2. fluency in english 3. understanding and willingness to comply with study requirements 4. waitlisted for outpatient psychosocial programming at camh (or psychosocial programming in the community) 5. smartphone or tablet capable of downloading and running the mindfulness app. exclusion criteria: 1. any known practical factor that would preclude participation (e.g., extended absences) 2. acute psychiatric (e.g., acute suicidality, psychosis) or serious medical condition that precludes participation in this study. 3. participation in another treatment/intervention study

Keywords: mindfulness digital health
dose-dependent effects of second-hand smoke on vascular function

Conditions: Cardiovascular Disease

Summary: the purpose of this study is to determine the vascular effects of brief second-hand smoke exposure on normal healthy individuals.

second-hand smoke remains a significant public health threat. despite evidence to suggest that secondhand smoke contributes to adverse cardiovascular outcomes, little is known about the dose-dependent vascular effects of brief secondhand smoke exposure at low doses commonly encountered in the community. this study will investigate the acute vascular effects and dose-dependent biological mechanisms of secondhand smoke on endothelial function and oxidative stress.

Eligibility criteria:
inclusion criteria: * healthy non-smoking adults exclusion criteria: * reported active smoking * history of diabetes, hypertension, chronic respiratory disease, coronary artery disease, prior myocardial infarction or heart failure * pregnancy or breastfeeding * current use of prescription drugs within 14 days of trial * reported significant passive smoke exposure or elevated cotinine levels

Keywords: tobacco smoke oxidative stress endothelial function atherosclerosis arterial stiffness microvascular function
the efficacy and safety of using prophylactic abdominal drainage after cholecystectomy

Conditions: Drainage; Laparoscopic Cholecystectomy; Acute Cholecystitis

Summary: investigators want to assess the safety and efficacy of using abdominal drainage with not using any drainage, by estimating different outcomes after laparoscopic cholecystectomy for different reasons. patients are seen at the accident and emergency department or in the surgical wards at aleppo university hospital (auh) over 12 months period.

the routine use of prophylactic drainage has become common in many hospitals around the world after cholecystectomy for different reasons. in elective surgeries, the evidence does not support the use of drainage. but in emergency laparoscopic cholecystectomy surgeries, using drainage remains controversial. surgeons who support the use of drainage find it useful to identify the early complications of surgery and removing intra-abdominal collections, while opponents of drainage use believe that it increases the risk of wound infection. but, a systematic review and meta-analysis discussed the ineffectiveness of the routine use of the prophylactic drainage after laparoscopic cholecystectomy for acute cholecystitis and requested more randomized clinical trial studies on the subject. however, this study and others in the medical literature contain very few high-quality randomized controlled trials, hence our randomized controlled trial compares the use and non-use of drainage in patients undergoing laparoscopic cholecystectomy for different reasons.

Eligibility criteria:
inclusion criteria: * patients are seen at the accident and emergency department or in the surgical wards at aleppo university hospital (auh) over 12 months period. * patients who undergo cholecystectomy for any reason. exclusion criteria: * non-cooperative patients for regular follow up. * draining for therapeutic indications.

Keywords: prophylactic drainage laparoscopic cholecystectomy acute cholecystitis. upper gi surgery cholecystitis choledocholithiasis gallbladder diseases
lung ultrasound in the early detection of postoperative pulmonary complications after esophagectomy

Conditions: Esophageal Neoplasm

Summary: the perioperative management of esophageal cancer has evolved considerably in recent years. over the last 30 years, postoperative mortality has been steadily decreasing. however, respiratory morbidity remains high (30-40%). this is due to the procedure itself requiring a thoracic approach and intraoperative unipulmonary ventilation. the postoperative pulmonary complications (ppcs) are multiple: bronchial congestion, atelectasis, pneumopathy, acute respiratory distress syndrome (ards), liquid pleural effusion, pneumothorax. in general, prevention and early treatment are aimed at limiting the evolution towards acute respiratory failure requiring ventilatory assistance. chest radiography is essential for the presumptive diagnosis of pneumopathy in particular, but the interpretation of the images may be difficult. thoracic computed tomography (ct) is the gold standard because it is sensitive and can discriminate among differential diagnoses. this is difficult to perform: it requires intra-hospital transport of patient, who is often in acute respiratory failure, and the availability of an examination area. lung ultrasound is used at the bedside for diagnosis of lung infection in intensive care unit. this has a sensitivity close to thoracic ct and has the advantage of being feasible at any time, does not require transport of the patient and is not irradiating. lung ultrasound allows early detection of the need for ventilatory support in postoperative major abdominal surgery . in addition, the sensitivity of lung ultrasound is close to that of ct, allowing this examination to be relied upon. the main objective of the study is to determine the role of lung ultrasound in the prediction of postoperative pulmonary complications within one hour after extubation.


Eligibility criteria:
inclusion criteria: * thoracic esophagectomy exclusion criteria: * emphysema death during surgery refusal

Keywords: thoracic esophagectomy esophagectomy postoperative pulmonary complications lung ultrasound critical care
observational study to assess the quality of life in nephropathic cystinosis patients

Conditions: Nephropathic Cystinosis

Summary: most of the real world evidence data related to efficacy of cysteamine therapy is retrospective. this study is a ambispective study to investigate the impact of cystine depletion therapy on the quality of life of patients and their parents.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of nephropathic cystinosis * undergoing cystine depletion therapy with oral cysteamine * signature of informed concent.
dpbrn blood sugar testing in dental patients

Conditions: Diabetes Mellitus; Hyperglycemia

Summary: the principal goal of this study was to assess the feasibility of plasma glucose testing in private dental practice. a second aim was was to assess prevalence of plasma glucose abnormalities in dental patients seen by (dpbrn) practitioner-investigators.

the specific aims of this study were: 1. to quantify the percentage of (dpbrn) patients who meet the american diabetes association screening criteria and to describe the characteristics of these patients. 2. to quantify the acceptability of conducting glucose testing in the dental office and barriers to regular screening, as reported by (dpbrn) patients and practices.

Eligibility criteria:
inclusion criteria: * adults over the age of 19 who were scheduled for a visit with an exam exclusion criteria: * patients undergoing continuing treatment where an exam was not part of the visit were not eligible

Keywords: glucose testing
a randomized trial of rhtpo versus placebo for low/intermediate-1 risk mds with thrombocytopenia

Conditions: Low/Intermediate Risk-1 MDS

Summary: myelodysplastic syndrome (mds) is a kind of clonal myeloid tumor. the major manifestation is decrease of tri-lineages of blood due to ineffective and abnormal hematopoiesis, some of which can progress to acute myeloid leukemia. according to the international prognosis scoring system (ipss) of mds, about 10% low/intermediate risk-1 mds patients have severe thrombocytopenia (plt \< 30 × 109/ l). these patients have both decreased platelet count and platelet dysfunction, resulting in a high risk of bleeding. in the new prognostic score, such as ipss-r, the degree of thrombocytopenia is regarded as a poor prognostic factor. platelet transfusion is mainly used in the treatment of this kind of patients. the indications of transfusion include bleeding events or severe platelet count reduction (\< 10 × 109 / l). however, platelet transfusion can only lead to short-term platelet elevation, while repeated transfusion increases the possibility of infection and ineffective platelet transfusion. tpo is a newly discovered hematopoietic promoting factor, which can specifically bind to the tpo receptor on the cell and participate in the regulation of proliferation, differentiation, maturation and division of megakaryocyte to form functional platelet. the efficacy and safety of the tpo receptor agonists eltrombopag and romiplostim in the treatment of thrombocytopenia in low/intermediate risk-1 mds patients have been successfully confirmed in foreign studies. recombinant human thrombopoietin (rhtpo) is also a kind of a tpo receptor agonists which is highly specific platelet stimulating factor. at present, there is no large report on the application of rhtpo in such patients. the purpose of this study is to explore the short-term and long-term therapeutic effect and safety of rhtpo on low/intermediate risk-1 mds patients.


Eligibility criteria:
inclusion criteria: 1. confirmed mds, ipss low / intermediate risk-1 2. in the 4 weeks before inclusion, the average value of platelets was ≤ 30 × 10e9 / l, or \< 50 × 10e9 / l with bleeding events 3. patients with epo due to anemia and g-csf due to severe neutropenia can be included, and the dosage will not change during trial 4. baseline liver and kidney function: alt / asl within 3 times normal upper limit, tbil within 2 times normal upper limit, and creatinine within 2 times normal upper limit 5. ecog 0-2 points 6. able to sign informed consent exclusion criteria: 1. pregnant or lactating 2. ipss intermediate risk-2 / high risk mds 3. more than 5% of myeloblasts in bone marrow 4. myelofibrosis 5. previous transplantation or atg treatment within 6 months 6. previous use of il-11, tpo or other tpo receptor agonists 7. active infection or tumor 8. thromboembolic or hemorrhagic disease 9. serious heart disease, including unstable angina, congestive heart failure, arrhythmia, 1-year history of myocardial infarction 10. intracranial hemorrhage within 4 weeks